Abstract:Telomerase is highly expressed in tumor cells, which has become an important target of anticancer drugs. Since many tumor cells were rich in G4-DNA, we investigated the capabilities of these two ruthenium complexes to stabilize G4-DNA. Two ruthenium(II) complexes were synthesized and characterized via electrospray ionization-mass spectrometry. Since many tumor cells were rich in G4-DNA, we investigated the capabilities of these two ruthenium complexes to stabilize G4-DNA. The interactions of these corn. pounds with G-quadruplex DNA have been studied by fluorescence spectroscopy and circular dichroism (CD) spectroscopy. The stabilization of quadruplex DNA to complex 2 was better than complex 1, and complex 2 can induce telomeric G-quadruplex to occur conformation transformation, while complex 1 cannot. The results showed that the interaction of ruthenium complexes with G-quadruplex DNA was related with the plane of ligand. A novel visual method has been developed for making a distinction between ct-DNA and HTG21 by our Ru complexes binding hemin to form the hemin-G-quadruplex DNAzyme. The results showed that in the presence of complex 1 or 2, HTG21 can fold into a G-quadruplex, but CT-DNA cannot form the G-quadruplex structure. The anticancer activities of these complexes were evaluated by using the MTT assay. Interestingly, the anti-tumor activity of complex 2 exhibited greater inhibition to HepG2 cells, suggesting the ruthenium complexes were much less toxic towards normal cells, and speculated that it targeted the telomeric G-quadruplex was play a role on anti-tumor effect. To further evaluate the characteristics of the death induced by complexes 1 and 2-treated cells staining with Hoechst is analyzed by fluorescence microscopy. These results indicated that complex 2 revealed antiproliferative activities by apoptosis. We also used PI staining and flow cytometry to assess whether the ruthenium complex 2 affected cell cycle progression in HepG2 cells. Complex 2 is a potential antitumor drugs that can induce cancer cell death by acting on cell cycle arrest in G1 phase and the formation of DNA fragments (apoptosis characteristics).

Chiral RuII‐PtIIComplexes Inducing Telomere Dysfunction Against Cisplatin‐Resistant Cancer Cells

Chiral Ruthenium(Ii) Polypyridyl Complexes: Stabilization of G-Quadruplex Dna, Inhibition of Telomerase Activity and Cellular Uptake

Stabilization of G-quadruplex DNA, Inhibition of Telomerase Activity and Live Cell Imaging Studies of Chiral Ruthenium(ii) Complexes.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Novel Chiral Ru(II) Complexes as Potential c-myc G-quadruplex DNA Stabilizers Inducing DNA Damage to Suppress Triple-Negative Breast Cancer Progression

Stabilization of Telomere DNA, and Mechanism of Apoptosis of Tumor Cells Induced by Ruthenium Complexes

Targeting Human Telomeric G-Quadruplex Dna And Inhibition Of Telomerase Activity With [(Dmb)(2)Ru(Obip)Ru(Dmb)(2)](4+)

Two Novel Fan-Shaped Trinuclear Pt(ii) Complexes Act As G-quadruplex Binders and Telomerase Inhibitors

G-quadruplex DNA selective targeting for anticancer therapy: a computational study of a novel PtII monofunctional complex activated by adaptive binding.

A Trifunctional Pt(II) Complex Alleviates the NHEJ/HR-related DSBs Repairs to Evade Cisplatin-Resistance in NSCLC.

A Ruthenium(ii) Complex Capable of Inducing and Stabilizing Bcl-2 G-quadruplex Formation As a Potential Cancer Inhibitor.

V-Shaped Dinuclear Pt(II) Complexes: Selective Interaction with Human Telomeric G-quadruplex and Significant Inhibition towards Telomerase

Cyclometalated Ru(II)-isoquinoline Complexes Overcome Cisplatin Resistance of A549/DDP Cells by Downregulation of Nrf2 Via Akt/GSK-3β/Fyn Pathway

Pt(Ii) Squares As Selective and Effective Human Telomeric G-Quadruplex Binders and Potential Cancer Therapeutics

Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway

Platinum(ii) Clovers Targeting G-quadruplexes and Their Anticancer Activities

Three Ru(II) complexes modulate the antioxidant transcription factor Nrf2 to overcome cisplatin resistance

A novel platinum(II) complex with berberine derivative as potential antitumor agent targeting G-quadruplex DNA

Targeting topoisomerase II with the chiral DNA-intercalating ruthenium(II) polypyridyl complexes

Targeting nucleus DNA with a cyclometalated dipyridophenazineruthenium(II) complex.

Anticancer Activity of Novel Ruthenium Complex with 1,10-Phenanthrolineselenazole As Potent Telomeric G-Quadruplex Inhibitor